

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

Database of prOkaryotic OpeRons

RRID:SCR_007593

Type: Tool

Proper Citation

Database of prOkaryotic OpeRons (RRID:SCR_007593)

Resource Information

URL: <http://csbl1.bmb.uga.edu/OperonDB/>

Proper Citation: Database of prOkaryotic OpeRons (RRID:SCR_007593)

Description: DOOR (Database of prOkaryotic OpeRons) is an operon database. The operons in the database are based on prediction. The database provides an organism view, gene search, operon search, and operon prediction tools. Currently DOOR has operons for 675 prokaryotic genomes.

Synonyms: DOOR

Resource Type: data or information resource, database

Keywords: operon, operon prediction, prokaryote, prokaryotic genome

Resource Name: Database of prOkaryotic OpeRons

Resource ID: SCR_007593

Alternate IDs: nif-0000-02762

Record Creation Time: 20220129T080242+0000

Record Last Update: 20260905T133140+0000

Ratings and Alerts

No rating or validation information has been found for Database of prOkaryotic OpeRons.

No alerts have been found for Database of prOkaryotic OpeRons.

Data and Source Information

Usage and Citation Metrics

We found 69 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Howard-Anderson J, et al. (2026) Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections. *Open forum infectious diseases*, 13(6), ofag320.

Adelheid K, et al. (2026) Frequency and outcomes of surgical and transcatheter closure of patent ductus arteriosus in preterm infants in Germany-a prospective nationwide hospital-based surveillance study. *European journal of pediatrics*, 185(6).

Rose N, et al. (2026) Linezolid in addition to standard antibiotic treatment for *Staphylococcus aureus* bacteraemia: study protocol for a randomised, placebo-controlled trial. *BMJ open*, 16(4), e118509.

Gottesdiener LS, et al. (2026) Resistance to novel β -lactam/ β -lactamase inhibitors among carbapenem-resistant *Pseudomonas aeruginosa* and clinical implications in the prospective observational *Pseudomonas* study. *Antimicrobial agents and chemotherapy*, 70(6), e0038825.

Banerjee R, et al. (2025) Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trial. *Trials*, 26(1), 500.

Johns BP, et al. (2025) Comparison of surgical treatments for hip and knee periprosthetic joint infections using the desirability of outcome ranking in a prospective multicentre study. *Journal of bone and joint infection*, 10(2), 73.

VanBuren JM, et al. (2025) Evaluating the desirability of outcome ranking and response adjusted for duration of antibiotic risk for clinical trials of antibiotics in pediatric pneumonia. *American journal of epidemiology*, 194(4), 1090.

McDonald EG, et al. (2025) Is there a role for anticoagulation with dabigatran in *S. aureus* bacteremia? Protocol for the adjunctive treatment domain of the *Staphylococcus aureus* Network Adaptive Platform (SNAP) randomised controlled trial. *BMJ open*, 15(12), e107493.

Yogendrakumar V, et al. (2024) Evaluating the Safety and Efficacy of Telemedicine Physician Assessments on a Mobile Stroke Unit: Protocol for a Prospective Open-Label Blinded End-Point Randomized Controlled Trial. *Journal of the American Heart Association*, 13(21), e036856.

Vivash L, et al. (2023) The adaptation of the desirability of outcome ranking for interventional clinical trials in epilepsy: A novel consumer-led outcome measure. *Epilepsia*

open, 8(4), 1608.

Lee AJ, et al. (2023) Compendium-Wide Analysis of *Pseudomonas aeruginosa* Core and Accessory Genes Reveals Transcriptional Patterns across Strains PAO1 and PA14. *mSystems*, 8(1), e0034222.

Gao Y, et al. (2023) The *Escherichia coli* Fur pan-regulon has few conserved but many unique regulatory targets. *Nucleic acids research*, 51(8), 3618.

Gupta N, et al. (2022) A comprehensive approach to discover Toxin-Antitoxin systems from human pathogen *Helicobacter pylori*: A poison and its antidote encapsulated in the genome. *Life sciences*, 288, 120149.

Merchante N, et al. (2022) Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. *Antimicrobial agents and chemotherapy*, 66(2), e0210721.

Howard-Anderson JR, et al. (2022) Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales. *Infection control and hospital epidemiology*, 43(12), 1840.

Tagini F, et al. (2021) Pathogenic Determinants of the *Mycobacterium kansasii* Complex: An Unsuspected Role for Distributive Conjugal Transfer. *Microorganisms*, 9(2).

Poudel S, et al. (2021) Identification and characterization of proteins of unknown function (PUFs) in *Clostridium thermocellum* DSM 1313 strains as potential genetic engineering targets. *Biotechnology for biofuels*, 14(1), 116.

Barlow A, et al. (2021) Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection. *Infectious diseases and therapy*, 10(1), 605.

Brenner T, et al. (2021) Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial. *Trials*, 22(1), 714.

Liu T, et al. (2021) Position preference of essential genes in prokaryotic operons. *PloS one*, 16(4), e0250380.